Synendos Therapeutics

Executive Summary

Synendos Therapeutics is a clinical-stage Swiss biotech targeting the endocannabinoid system (ECS) with first-in-class small molecules for neuropsychiatric disorders. Its lead program, SYT-510, is a Selective Endocannabinoid Reuptake Inhibitor (SERI) aimed at restoring ECS balance to treat anxiety and mood disorders such as Generalized Anxiety Disorder (GAD) and Post-Traumatic Stress Disorder (PTSD). By modulating the ECS, Synendos offers a novel mechanism distinct from traditional neurotransmitter-based therapies, potentially addressing unresolved safety and efficacy gaps. The company is currently advancing SYT-510 through Phase 2 trials, with a focus on demonstrating proof-of-concept in GAD. To date, Synendos has raised significant early-stage funding and benefits from strong scientific leadership in Basel. The upcoming catalysts center on clinical data readouts that could validate SYT-510's therapeutic potential and de-risk its path to Phase 3. Positive results would not only support registration trials but also attract strategic partnerships for commercialization. As a private company, key milestones include trial enrollment completion, interim efficacy analyses, and potential financing rounds to extend the cash runway into late-stage development.

Upcoming Catalysts (preview)

• Q3 2026Phase 2a Topline Data for SYT-510 in GAD50% success
• Q1 2027Initiation of Phase 2b Dose-Finding Trial for SYT-51070% success
• H2 2026Series C Financing or Partnership Deal60% success